Rethinking Intelligence Quotient Exclusion Criteria Practices in the Study of Attention Deficit Hyperactivity Disorder

被引:23
|
作者
Mackenzie, Genevieve B. [1 ]
Wonders, Elif [2 ]
机构
[1] Univ Toronto, Ontario Inst Studies Educ, Attent Deficit Hyperact Disorder & Literacy Lab, Toronto, ON, Canada
[2] McGill Univ, Dept Educ & Counselling Psychol, Connect Lab, Montreal, PQ, Canada
来源
FRONTIERS IN PSYCHOLOGY | 2016年 / 7卷
关键词
attention deficit/hyperactivity disorder; intelligence quotient; exclusion criteria; inclusion criteria; mild intellectual impairment; SLUGGISH COGNITIVE TEMPO; DEFICIT/HYPERACTIVITY DISORDER; CHILDREN; ADHD; IQ; ATOMOXETINE; ADOLESCENTS; INHIBITION; ADULTS; METHYLPHENIDATE;
D O I
10.3389/fpsyg.2016.00794
中图分类号
B84 [心理学];
学科分类号
04 ; 0402 ;
摘要
Attention deficit hyperactivity disorder (ADHD) is associated with lower than average intelligence quotient (IQ) scores. However, research done on this disorder often excludes participants based on lower than average IQ's (i.e., between 70 and 85). The purpose of this paper is to alert researchers to the consequences of excluding participants based on IQ's within this range and to highlight the importance of providing a clear rationale when choosing to exclude participants based on IQ. Next, we offer recommendations for researching ADHD and their relative benefits and drawbacks of these approaches. Overall this paper emphasizes that including participants who have lower than average IQ in research on ADHD may promote a more realistic understanding of the condition and in turn improve our ability to treat it.
引用
收藏
页数:5
相关论文
共 50 条
  • [21] Oral health of children with attention deficit hyperactivity disorder
    Chau, Yvonne C. Y.
    Lai, Kelly Y. C.
    McGrath, Colman P. J.
    Yiu, Cynthia K. Y.
    EUROPEAN JOURNAL OF ORAL SCIENCES, 2017, 125 (01) : 49 - 54
  • [22] The management of attention-deficit hyperactivity disorder in children: Updated 2019
    Schellack, N.
    Meyer, J. C.
    Chigome, A. K.
    SA PHARMACEUTICAL JOURNAL, 2019, 86 (05) : 17 - 27
  • [23] Pozanicline for the treatment of attention-deficit/hyperactivity disorder
    Childress, Ann
    Sallee, Floyd R.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2014, 23 (11) : 1585 - 1593
  • [24] Attention Deficit Hyperactivity Disorder Treatment Practice in Turkey
    Oner, Ozgur
    Turkcapar, Hakan
    Isli, Fatma
    Karadag, Hasan
    Akbulat, Akif
    Basci, Ali Boray
    Aksoy, Mesil
    Seckin, Cem
    Alkan, Ali
    KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, 2016, 26 (03): : 265 - 272
  • [25] Adult attention-deficit/hyperactivity disorder: A survey of diagnosis and treatment practices
    Knutson, Kathleen C.
    O'Malley, Maureen
    JOURNAL OF THE AMERICAN ACADEMY OF NURSE PRACTITIONERS, 2010, 22 (11): : 593 - 601
  • [26] Rethinking attention deficit hyperactivity disorder
    Maiese, Michelle
    PHILOSOPHICAL PSYCHOLOGY, 2012, 25 (06) : 893 - 916
  • [27] Attention Deficit/Hyperactivity Disorder
    Prihodova, Iva
    CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE, 2011, 74 (04) : 408 - 418
  • [28] Viloxazine for the Treatment of Attention Deficit Hyperactivity Disorder
    Robinson, Christopher L.
    Parker, Katelyn
    Kataria, Saurabh
    Downs, Evan
    Supra, Rajesh
    Kaye, Alan D.
    Viswanath, Omar
    Urits, Ivan
    HEALTH PSYCHOLOGY RESEARCH, 2022, 10 (03):
  • [29] Treatment of Attention-Deficit/Hyperactivity Disorder
    Pierce, Karen
    PEDIATRIC ANNALS, 2011, 40 (11): : 556 - 562
  • [30] Neurofeedback for Attention-Deficit/Hyperactivity Disorder
    Westwood, Samuel J.
    Aggensteiner, Pascal-M.
    Kaiser, Anna
    Nagy, Peter
    Donno, Federica
    Merkl, Dora
    Balia, Carla
    Goujon, Allison
    Bousquet, Elisa
    Capodiferro, Agata Maria
    Derks, Laura
    Purper-Ouakil, Diane
    Carucci, Sara
    Holtmann, Martin
    Brandeis, Daniel
    Cortese, Samuele
    Sonuga-Barke, Edmund J. S.
    European ADHD Guidelines Group
    JAMA PSYCHIATRY, 2025, 82 (02) : 118 - 129